Increased T cell proliferative responses to islet antigens identify clinical responders to anti-CD20 monoclonal antibody (rituximab) therapy in type 1 diabetes.
about
Type 1 diabetes: translating mechanistic observations into effective clinical outcomesDiabetes and immune thrombocytopenic purpura: a new association with good response to anti-CD20 therapy.Recommendations for the definition of clinical responder in insulin preservation studiesReduction in CD4 central memory T-cell subset in costimulation modulator abatacept-treated patients with recent-onset type 1 diabetes is associated with slower C-peptide decline.Altered B cell homeostasis and toll-like receptor 9-driven response in type 1 diabetes carriers of the C1858T PTPN22 allelic variant: implications in the disease pathogenesisThe dual effects of B cell depletion on antigen-specific T cells in BDC2.5NOD mice.The importance of the Non Obese Diabetic (NOD) mouse model in autoimmune diabetesMolecular imaging of atherosclerosis for improving diagnostic and therapeutic developmentRituximab does not reset defective early B cell tolerance checkpointsNew and future immunomodulatory therapy in type 1 diabetes.Reactivation of latent viruses in individuals receiving rituximab for new onset type 1 diabetes.Life and death of β cells in Type 1 diabetes: A comprehensive review.Targeting regulatory T cells in the treatment of type 1 diabetes mellitus.Effect of abatacept on immunogenicity of vaccines in individuals with type 1 diabetes.Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders.Involvement of suppressive B-lymphocytes in the mechanism of tolerogenic dendritic cell reversal of type 1 diabetes in NOD miceLarge-scale prospective T cell function assays in shipped, unfrozen blood samples: experiences from the multicenter TRIGR trial.Red carpeting the newer antidiabetics.Immunologic and metabolic biomarkers of β-cell destruction in the diagnosis of type 1 diabetes.Autoimmunity in 2011.The long-term marriage between autoimmunity and internal medicine: a homage to Manuel Carlos Dias.Cell-based interventions to halt autoimmunity in type 1 diabetes mellitus.Type 1 diabetes therapy beyond T cell targeting: monocytes, B cells, and innate lymphocytesBiomarkers in type 1 diabetes: application to the clinical trial setting.Reestablishing T Cell Tolerance by Antibody-Based Therapy in Type 1 Diabetes.Less is more: the detrimental consequences of immunosuppressive therapy in the treatment of type-1 diabetes.Rituximab in Minimal Change Disease: Mechanisms of Action and Hypotheses for Future Studies.The elusive role of B lymphocytes and islet autoantibodies in (human) type 1 diabetes.Have we pushed the needle for treatment of Type 1 diabetes?Intestinal type 1 regulatory T cells migrate to periphery to suppress diabetogenic T cells and prevent diabetes development.
P2860
Q28287737-5EDB6076-6E92-4B78-8EBB-496CDC8D9505Q33413423-DA93CB7A-168F-4296-85F2-04A0A08E51D4Q34077400-6E51ED28-2E0E-441F-AB17-B0A76D2C7392Q34227866-016670F9-9F51-40D5-BC1B-B13EC3A9047BQ34380329-600E873B-BF8F-4862-A1AB-822C98C7D8FBQ35180980-2DBA6E2E-F35A-4D5B-B4A9-43721A457537Q35787117-B39BD3C0-D664-41A8-ADD8-AAF7F041C0A5Q36141999-C28E33EA-79AD-4F94-B2F3-D64CFB6B4BACQ36430775-664B8B64-2625-440D-B096-3C467173460BQ36650474-751740A1-7B11-4F18-AE57-8C537B6473EAQ36807999-9BCA456A-2EB0-4656-92FF-CA967081851FQ36995568-6F88868A-34E7-432A-BA1E-D5A65D284FDCQ37006155-A50F76EC-8E07-4EDC-83F0-F8E750F3BBA8Q37243204-FA35B4D0-93F8-4D95-9073-70D58ADCE6ACQ37251153-4147ABA3-4A1B-4328-8CBF-67146A3FA5EBQ37490637-0FCBD0F3-7847-4E22-9938-0CE07EBA1862Q37544980-15F573A3-EBA7-4012-933D-DCD3008A1F51Q38013105-3C455F46-0084-428C-B1AC-C72004922ACBQ38016902-B28F3D28-CCC4-44E5-8A44-C92EF46934D5Q38021696-7E1EF857-73C1-4BE8-BE63-9EFEDBBD4CEEQ38028889-1F0C422F-73E4-4812-8F50-CA4A4A49CBFBQ38071420-7560E29C-22CE-4D91-80B7-D7198412A357Q38117282-C12C6AB6-BD36-40BF-8924-6489858F8C04Q38220863-0ACD3454-E0D1-4C5A-8BE4-F7F2D256D75AQ38384138-4426BE90-3105-4B1C-9EA1-6CCE5FAE1B8EQ38385236-DE3E98EF-1427-4532-8D49-07BF2FA3DE62Q38679589-AB62B5BB-FE76-4DB3-B9D0-F604341390BDQ47577827-ED31073E-E19B-4450-8724-32C834B0445BQ47907621-2FA99832-1586-429C-B070-AB1BACC290B1Q48000827-53B9AFFF-7469-4349-8438-9C9506140F91
P2860
Increased T cell proliferative responses to islet antigens identify clinical responders to anti-CD20 monoclonal antibody (rituximab) therapy in type 1 diabetes.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Increased T cell proliferative ...... b) therapy in type 1 diabetes.
@ast
Increased T cell proliferative ...... b) therapy in type 1 diabetes.
@en
type
label
Increased T cell proliferative ...... b) therapy in type 1 diabetes.
@ast
Increased T cell proliferative ...... b) therapy in type 1 diabetes.
@en
prefLabel
Increased T cell proliferative ...... b) therapy in type 1 diabetes.
@ast
Increased T cell proliferative ...... b) therapy in type 1 diabetes.
@en
P2093
P2860
P356
P1476
Increased T cell proliferative ...... b) therapy in type 1 diabetes.
@en
P2093
Adam Asare
H Michael Dosch
Heidi Krause-Steinrauf
Kasia Bourcier
Kevan C Herold
Lisa M Spain
Mark D Pescovitz
Paula McGee
Type 1 Diabetes TrialNet Anti-CD20 Study Group
Zhugong Liu
P2860
P304
P356
10.4049/JIMMUNOL.1100539
P407
P577
2011-07-20T00:00:00Z